Because TNF-alpha inhibitors have demonstrated clinical efficacy in various chronic inflammatory disorders,[11-13] a phase II, double-blind, multicenter, placebo-controlled clinical study was performed to evaluate the safety and efficacy of infliximab (Janssen Biotech, Inc., Horsham, PA, USA), an anti-TNF-alpha monoclonal antibody, in the treatment of COPD [14]. This evidence concerns the gene TNF and chronic obstructive pulmonary disease.